Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
BeovuⓇ - Anti-VEGF
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04047472 HOBBY (CRTH258A2307)
Macular degeneration
Phase 3
494
Change from baseline in best-corrected visual acuity (BCVA) at week 48
Brolucizumab (RTH258) 6 mg/50 μL
Aflibercept 2 mg/50 μL
Chinese patients with neovascular age-related macular degeneration
Target Patients
Read-out Milestone(s)
2024
Publication
TBD
105 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation